What is the Kala Pharmaceuticals, Inc. stock price forecast?

Kala Pharmaceuticals, Inc. is currently trading at $0.08. View real-time AI analysis on Alpha Lenz.

What is Kala Pharmaceuticals, Inc. insider trading activity?

View the latest insider trading data for Kala Pharmaceuticals, Inc. on Alpha Lenz.

What is Kala Pharmaceuticals, Inc.'s P/E ratio?

Kala Pharmaceuticals, Inc.'s P/E ratio is -0.0.

Kala Pharmaceuticals, Inc.

NASDAQ · KALA

$0.08-0.03(-27.74%)Market closed

Ask about Kala Pharmaceuticals, Inc.'s future dividend policy...

Alpha Chat Insight

“Kala Pharmaceuticals, Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -279.2%.”

Ask for details →

Company Overview

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for eye diseases. Its primary function is to address unmet needs in the field of ophthalmology by leveraging its proprietary AMPPLIFY™ drug delivery technology, which enhances the penetration of molecules into target tissues within the eye. This technology is pivotal in the treatment of various conditions, such as dry eye disease and inflammation and pain following ocular surgery. Kala Pharmaceuticals is actively working to impact the healthcare sector, particularly the ocular therapeutics segment, through products like EYSUVIS and INVELTYS. Headquartered in Massachusetts, the company plays a significant role in advancing patient care in the field of optometry and ophthalmology, contributing to the broader pharmaceutical and healthcare markets.

CEOMr. Todd Bazemore

Websitehttps://www.kalarx.com

SectorHealthcare

IndustryBiotechnology

Employees38

Company Statistics

FY 2025

Profile

$677.12KMarket Cap

$0.00Revenue

0.00Shares Out

38Employees

Margins

N/AGross

N/AEBITDA

N/AOperating

N/APre-Tax

N/ANet

Valuation

-0.03P/E

0.10P/B

N/AEV/Sales

0.21EV/EBITDA

-0.02P/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-83.05%ROA

-279.18%ROE

-72.97%ROIC

Financial Health

$7.56MCash & Cash Equivalents

$-5.06MNet Debt

35.65%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Kala Pharmaceuticals, Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -279.2%.”

Ask for details →

Frequently Asked Questions

Kala Pharmaceuticals, Inc. (ticker: KALA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 38 employees. Market cap is $677,122.

The current price is $0.083 with a P/E ratio of -0.03x and P/B of 0.1x.

ROE is -279.18%.